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Key Points
• Reducing therapy intensity in
the ML-DS 2006 trial did not
impair the excellent prognosis
in ML-DS compared with the
historical control.
• Early treatment response and
gain of chromosome 8 are
independent prognostic
factors.
Children with myeloid leukemia associated with Down syndrome (ML-DS) have superior
outcome compared with non-DS patients, but suffer from higher constitutional cytotoxic drug
susceptibility. We analyzed the outcome of 170 pediatric patients with ML-DS enrolled in the
prospective, multicenter, open-label, nonrandomized ML-DS 2006 trial by Nordic Society for
PediatricHematologyandOncology (NOPHO),DutchChildhoodOncologyGroup (DCOG), and
Acute Myeloid Leukemia–Berlin-Frankfurt-Mu¨nster (AML-BFM) study group. Compared with
the historical control arm (reduced-intensity protocol for ML-DS patients from the AML-BFM
98 trial), treatment intensity was reduced by lowering the cumulative dose of etoposide (950 to
450 mg/m2) and intrathecal central nervous system prophylaxis while omitting maintenance
therapy.Still, 5-yearoverall survival (89%6 3%vs90%6 4%;Plog-rank5 .64), event-free survival
(EFS; 87% 6 3% vs 89% 6 4%; Plog-rank 5 .71), and cumulative incidence of relapse/
nonresponse (CIR/NR; 6%63%vs6%62%;PGray5 .03)didnot significantlydifferbetween
the ML-DS 2006 trial and the historical control arm. Poor early treatment response
(5-yearEFS, 58%616%vs88%63%;Plog rank5 .0008) andgainofchromosome8 (CIR/NR, 16%67%vs3%62%,PGray5 .02;5-yearEFS,
73%6 8% vs 91%6 4%, Plog rank5 .018) were identified as independent prognostic factors predicting a worse EFS. Five of 7 relapsed
patients (71%) with cytogenetic data had trisomy 8. Our study reveals prognostic markers for children with ML-DS and illustrates that
reducingtherapydidnot impairexcellentoutcome.ThetrialwasregisteredatEudraCTas#2007-006219-2. (Blood. 2017;129(25):3314-3321)
Introduction
Children with Down syndrome (DS) have a 150-fold increased risk
of myeloid leukemia (ML) before the age of 5 years.1 The majority of
the reported cases with ML associated with DS (ML-DS) show a
predominance ofmegakaryoblasts, corresponding tomegakaryoblastic
leukemia (AMKL) or French-American-British (FAB)-type M7 in
non-DS patients.2-4 ML-DS can be preceded by a period of transient
abnormalmyelopoiesis (TAM).5BothML-DSandTAMareassociated
with mutations of the hematopoietic transcription factor GATA1,6
which is causative during leukemogenesis.7
Historically, outcome in children with ML-DS was thought to be
poor.8 To date, excellent cure rates have been achieved for ML-DS
using dose-reduced treatment protocols without hematopoietic stem
cell transplantation.9-15 The reduced-intensity arm for ML-DS of the
Acute Myeloid Leukemia–Berlin-Frankfurt-Mu¨nster (AML-BFM) 98
trial consisted of 4 courses of chemotherapy, containing cytarabine,
idarubicin, etoposide, or mitoxantrone, and resulted in event-free
survival (EFS) after 5 years of 89%.9 This is in contrast to a 5-year EFS
of 54% in non-DS children with AML FAB M7 (non-DS-AMKL).16
The excellent response was attributed to the enhanced drug sensitivity
of the ML-DS blasts, especially to cytarabine and anthracyclines.17,18
Still, despite reduced intensity, many patients suffer from therapy-
associated toxicity.9 This determines therapy-related mortality (TRM)
as the main cause of death in this cohort of patients.9-15
Different international study protocols for ML-DS vary in their
treatment intensity and drug scheduling.9-15 Whereas recent North
American and European studies use high doses of anthracyclines and
cytarabine,9-13 Japanese studies achieved comparable survival rates
using less intense treatment regimens.14,15 In contrast, the prognosis of
relapsed ML-DS patients is extremely poor.12,19,20 This means that
ML-DS treatment schemata have to particularly strive for the balance
between appropriate chemotherapy dosage to avoid relapses and
treatment-related toxicity. Despite substantial efforts, clear prognostic
factors that identify those patients at high risk for relapse remain elusive
precluding a risk-adapted treatment strategy.21
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Here, we report the outcome of 170 pediatric patients with ML-DS
enrolled in the Myeloid Leukemia Down Syndrome 2006 (ML-DS
2006) trial, conducted by the Nordic Society for Pediatric Hematology
and Oncology (NOPHO), Dutch Childhood Oncology Group
(DCOG), and AML-BFM study group. The protocol was based on the
reduced-intensity arm for children with ML-DS in the AML-BFM 98
trial andwas further intensity-reduced by excluding etoposide from the
consolidation phase (reducing the cumulative dose from 950mg/m2 to
450 mg/m2), administering 4 instead of 11 doses of intrathecal central
nervous system (CNS) prophylaxis (cytarabine 20-40 mg), and ex-
cluding maintenance therapy.9 The aim of the trial was to assure the
high EFS while further reducing the risk of treatment-related toxicity.
Methods
Patients
The ML-DS 2006 (EurdraCT #2007-006219-22) is a multicenter, open-label,
nonrandomized trial running in Germany, Austria, Switzerland, the Czech
Republic (BFM), Scandinavia (NOPHO), and The Netherlands (DCOG). It was
opened on January 1, 2007 and closed on August 30, 2015. The ﬁnal protocols
were approved by the local ethic committees according to national laws and
regulations. The trialwas carried out according to theDeclarationofHelsinki, the
principles of Good Clinical Practice and Directive 2001/20/EC of the European
Parliament and of the Council of April 4, 2001.
Patients with ML-DS with evidence of megakaryoblasts or undifferentiated
blasts, conﬁrmed by morphology and immunophenotyping (including CD34,
CD117, CD7, CD13, CD33, CD15, CD36, CD56, CD41, CD42b, CD61) in the
bonemarrow (BM), peripheral blood, or trephine biopsy, between 6months and
4 years were eligible for participation after legal written informed consent of the
parents/custodians. Immunophenotyping was done and centrally reviewed by
each collaborative studygroup (AML-BFM,DCOG,NOPHO).TheAML-BFM
and DCOG group performed central review of morphology. Patients older than
4 years of age andyounger than 18yearswere included if aGATA1mutationwas
detected. Independent of age, DS patients with AML FAB M1-M5 were not
eligible for the reduced-intensity ML-DS 2006 protocol as those cases were
suspected to represent rare sporadic acute myeloid leukemia (AML) occurring
in patients with DS with a different underlying biology and with a different
treatment response compared with ML-DS.22 The World Health Organization
(WHO) and FAB classiﬁcations were used for the initial diagnosis of AML.2,3
The diagnoses of the FAB M0 and M7 subtypes required conﬁrmation by
immunologicmethods.3,23,24 Inbrief, for thediagnosisofFAB,M0blastshad tobe
negative formyeloperoxidase activity and for B- andT-cellmarkers (except CD7)
and show expression ofmyeloid antigens (CD117,CD13, orCD33).Diagnosis of
FABM7was considered when blasts were negative for myeloperoxidase activity
and had speciﬁc megakaryocytic markers (CD41, CD42b, and/or CD61) without
anyB-orT-cellmarkers (exceptCD7).Surface antigen expressionwas considered
positive if at least 20% of blasts showed positive labeling.
Treatment of children with ML-DS in the AML-BFM 98 trial (historical
control arm) consisted of 4 cycles of polychemotherapy followed by
maintenance therapy as depicted in Figure 1. The AML-BFM 98 trial was
opened from August 1998 to July 2003 and recruited 67 children with ML-DS
(historical control arm) as previously described in detail.9
Treatment plan and study design
Treatment consisted of 4 cycles of polychemotherapy as depicted in Figure 1.
A good early response was deﬁned as,5% blasts in the BM at the start of the
second block. After every course, toxicity was evaluated using the National
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0
(CTCAE v3.0). The protocol required that each course should only be started if
the child is in a good general condition without clinical signs of an infection,
mucositis, or fever and with recovery of blood counts (neutrophil count,
.1 3 109/L; and platelets, .80 3 109/L).
No recommendations for antibiotic or antifungal prophylaxis were made by
the study protocol.
The primary objective of the ML-DS 2006 trial was to achieve a 5-year
overall survival (OS) of 85% in 150 recruitedpatientswith a standard error,5%.
The secondaryobjectiveswere to reduce toxicitywithout impairment of outcome
and identify prognostic factors (cytogenetics, clinical parameters at diagnosis,
GATA1 status, and treatment response assessed by morphology prior to the
commencement of each course of chemotherapy) concerning the risk of relapse,
toxicity, and poor outcome. Therefore, the end points of the trial were response
rate (complete remission [CR]), EFS, disease-free survival, OS, and TRM.
Interim analysis of response rate, frequency of relapse, and severe adverse events
was performed after inclusion of 50 and 100 patients by the data monitoring
committee. The criteria to close the protocol were .12 of 24 relapses or 10 of
20 deaths after inclusion of the ﬁrst 50 of 100 patients, respectively.
Cytogenetic and molecular genetic analyses
Cytogenetic and molecular genetic analyses (including GATA1 sequencing)
were done and centrally reviewed by each study group (AML-BFM, DCOG,
ML-DS 2006
AML-BFM 98
AIE AI haM
AIE
Day 0 21- 28 42- 54 88 ~112 ~140
AI haM
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M
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Figure 1. ML-DS 2006 protocol compared with the historical control arm (AML-BFM 98). Scheme of the different study protocols as indicated. ML-DS 2006: AIE
(cytarabine 100 mg/m2 per day [days 1-2] and 100 mg/m2 per 12 hours [days 3-8], idarubicin 8 mg/m2 per day [days 3, 5, and 7], and etoposide 150 mg/m2 per day [days 6-8]);
AI (cytarabine 500 mg/m2 per day [days 1-4] and idarubicin 5 mg/m2 per day [days 3 and 5]); haM (cytarabine 1 g/m2 per 12 hours [days 1-3] and mitoxantrone 7 mg/m2 per
day [days 3-4]); HA (high-dose cytarabine 3 g/m2 per 12 hours [days 1-3]). The cumulative doses were 27 400 mg/m2 cytarabine, 450 mg/m2 etoposide, 34 mg/m2 idarubicin,
and 14 mg/m2 mitoxantrone. Chemotherapy for children younger than 12 months of age, or weighing ,12 kg, was calculated based on body weight. In addition, patients
received cytarabine intrathecally at the start of each treatment block (4 doses in total, 20-40 mg per dose adapted to age) as a CNS prophylaxis. AML-BFM 98 (reduced-
intensity arm for children with ML-DS; historical control arm): AIE (cytarabine 100 mg/m2 per day [days 1-2] and 100 mg/m2 per 12 hours [days 3-8], idarubicin 8 mg/m2 per
day [days 3, 5, and 7] and etoposide 150 mg/m2 per day [days 6-8]); AI (cytarabine 500 mg/m2 per day [days 1-4] and idarubicin 5 mg/m2 per day [days 3 and 5]); haM
(cytarabine 1 g/m2 per 12 hours [days 1-3] and mitoxantrone 7 mg/m2 per day [days 3-4]); HAE (high-dose cytarabine 3 g/m2 per 12 hours [days 1-3] and etoposide
125 mg/m2 per day [days 2-5]). Maintenance therapy until 1.5 years after start of induction therapy was thioguanine daily 40 mg/m2 per os (p.o.) and cytarabine
40 mg/m2 subcutaneously (s.c.) every 4 weeks on 4 consecutive days. The cumulative doses were ;29 400 mg/m2 cytarabine, 950 mg/m2 etoposide, 34 mg/m2
idarubicin, and 14 mg/m2 mitoxantrone.
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NOPHO). For theAML-BFMgroup, the reference laboratories performedand
centrally reviewed cytogenetic (Hannover, Giessen, Germany) andmolecular
genetic analyses (Essen,Hannover,Germany) as previously described.6,24 For
the DCOG, cytogenetic analyses were done by the university cytogenetic
laboratories inTheNetherlands and reviewed by a national cytogenetic review
panel. Molecular genetic analyses were performed at the Erasmus MC
(Rotterdam, TheNetherlands).6 ForNOPHO, cytogenetic analyseswere done
by the university cytogenetic laboratories in the member countries and
reviewed by the NOPHO cytogenetic review panel as previously described.25
GATA1 analyses were performed by the Weatherall Institute of Molecular
Medicine (Oxford, United Kingdom).6 Complete karyotypes were described
according to the International System of Human Cytogenetic Nomenclature
(ISCN).26
Statistics
CR was deﬁned by fulﬁllment of the Cancer and Leukemia Group B (CALGB)
criteria,27 early death (ED) being death before or within the ﬁrst 6 weeks of
treatment.EFSwasdeﬁned as time fromdiagnosis to theﬁrst event or last follow-
up. Events were death from any cause, failure to achieve remission, relapse, and
secondary malignancy. Failure to achieve remission was considered as an event
onday 0. Survivalwas deﬁned as the timeof diagnosis to death fromanycause or
last follow-up.
TheKaplan-Meiermethodwas used to estimate survival rates.28 Differences
were compared with the 2-sided log-rank test.29 Standard errors (SEs) were
obtained using the Greenwood formula. Cumulative incidence of relapse/
nonresponse (CIR/NR) and death in CR were calculated by the method of
Kalbﬂeisch and Prentice and comparedwith theGray test. The Cox proportional
hazards model has been used to obtain the estimates and the 95% conﬁdence
interval (CI) of the relative risk for prognostic factors.30 Differences in the
distribution of individual parameters among patient subsets were analyzed using
the x2 test or Fisher exact test for categorized variables and the Mann-Whitney
U test for continuous variables.
Results
Patient characteristics
The population-based ML-DS 2006 trial enrolled 170 patients with de
novo ML-DS between 2006 and 2015. Patient characteristics are
summarized inTable 1 and are comparedwith the historical control arm
(ML-DS children from the AML-BFM 98 trial; N5 67).9 The median
follow-up for ML-DS 2006 was 4.0 years, and 9.6 years for the
historical control arm.
The median age at diagnosis was 1.6 years and the median white
blood cell (WBC) count was 5.13 109/L. None of theML-DS patients
had initial CNS involvement and only 4 patients (2.4%) had organ
involvement.GATA1mutationswere detected in 85.2% (n5 98) of the
ML-DS patients. However, as previously described,6 low blast count
or uncommon mutations outside of the genomic area, spanning the
polymerase chain reaction, or a deletion inside this area, affecting
the primer annealing site, may have resulted in a failure to detect the
GATA1 mutation in some cases. Compared with the AML-BFM 98
trial, patients in the ML-DS 2006 trial had a signiﬁcantly lower WBC
count (5.13 109/L vs 6.63 109/L; P5 .017) and higher hemoglobin
levels (9.3 g/dL vs 8.6 g/dL; P5 .033). Seventy-four patients (47.1%)
had,20% of blasts in the BM at diagnosis compared with only 18.2%
of the patients in the AML-BFM 98 trial (P, .001).
Treatment outcome
With a 5-year OS of 89% 6 3% and 5-year EFS of 87% 6 3%
(Figure 2A-B), children with ML-DS have an excellent outcome.
The CIR/NR was 6%6 2% (Figure 2C). In the AML-BFM98 trial
Table 1. Characteristics of ML-DS 2006 and AML-BFM 98 (ML-DS)
patients
ML-DS 2006 AML BFM 98
N % N % P
Total 170 100 67 100
Sex .475
Male 85 50 30 44.8
Female 85 50 37 55.2
FAB .016*
M0 4 2.8 6 9.1
M1/M2 — — — —
M3 — — — —
M4/M5 — — 1 1.5
M6 1 0.8 1 1.5
M7 124 96.9 58 87.9
Other — — — —
Age, y .788
,1 24 14.1 12 17.9
1 88 51.8 36 53.7
2 43 25.30 15 22.4
3 10 5.9 3 4.5
4 3 1.8 — —
$5 2 1.2 1 1.5
WBC, 109/L .014*
,10 144 87.3 47 70.1
10-20 13 7.9 13 19.4
20-50 4 2.4 4 6
$50 4 2.4 3 4.5
BM blasts, % <.001*
,20 74 47.1 12 18.2
$20 83 52.9 54 81.8
CNS involvement
No 136 100 64 100
Yes — — — —
Organ involvement .227
No 166 97.6 63 94
Yes 4 2.4 4 6
Case history, wk .094
,3 49 52.7 22 37.9
$3 44 47.3 36 62.1
TAM history .007
No 80 65 56 83.6
Yes 43 35 11 16.4
GATA1
WT 17 14.8
Mutated 98 85.2
Therapy response
Early death 2 1.2 — —
NR/PR — — — —
Relapse 9 5.3 4 6
Death in CCR 5 2.9 4 6
Secondary malignancy 3 1.8 1 1.5
LTFU in CCR 7 4.1 4 6
CCR 144 84.7 54 80.6
Median
Age, y 1.6 1.76 .752
WBC, 109/L 5.1 6.6 .017*
Hemoglobin, g/dL 9.3 8.6 .033*
BM blasts, % 20 29 <.001*
Follow-up, y 4.0 9.6
—, none; CCR, complete continuous remission; LTFU, lost to follow-up; PR,
partial response; WT, wild type.
*Bold P values are significant (,.05).
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(historicalcontrol arm;Figure1), the5-yearOS(90%64%;Plog-rank5 .64)
and 5-year EFS (89% 6 4%; Plog-rank 5 .71) were not signiﬁcantly
better (Figure 2A-B). The CIR/NR was 6% in both studies (PGray5
.95; Figure 2C), indicating that reducing the cumulative dose of
etoposide from 950 mg/m2 to 450 mg/m2 plus reducing CNS pro-
phylaxis and excluding maintenance therapy did not increase the
relapse risk.
During thewholeML-DS2006studyperiod,weobserved19events
(supplemental Table 1, see supplemental Data available on the Blood
Web site). Nine patients relapsed and 7 of those died. Two patients
died of cardiac failure and 3 patients died of infections (Streptococcus
mitis sepsis, fungal sepsis, and respiratory syncytial virus pneu-
monia, respectively). One patient died due to a severe macrophage
activation syndrome and another one due to a transfusion incident.
Three patients developed acute lymphoblastic leukemia (ALL) 1.6,
2.1, and 2.0 years after the end of chemotherapy, leading to death in
2 of those patients.We cannot concludewhether these cases represent
secondary leukemias or sporadic cases of ALL in a population that is
at high risk for development of ALL. Still, secondary cancer is rare in
DS1 and sporadic ALL has previously been well documented after
ML-DS.31
Interestingly, male patients showed superior outcome (5-year
OS, 98% vs 81%6 5%, Plog-rank5 .002; 5-year EFS, 94%6 3% vs
79% 6 5%, Plog-rank 5 .0075). Also, patients with a good early
response (n5 123) had signiﬁcantly better outcomewith a superior
5-year OS (92% 6 3% vs 57% 6 16%; Plog-rank , .0001), 5-year
EFS (88% 6 3% vs 58% 6 16%; Plog-rank 5 .0008), and a lower
CIR/NR (3% 6 2% vs 27% 6 18%, PGray 5 .003).
Cytogenetic analysis
Cytogenetic data were available for n5 122 patients (72%), which did
not signiﬁcantly differ from those patients without cytogenetic data
with respect to 5-year OS (89%6 3% vs 89%6 5%; Plog-rank5 .73),
5-year EFS (86%6 4% vs 89%6 5%; Plog-rank5 .94), and CIR/NR
(7% 6 2% vs 5% 6 3%; PGray 5 .73). Of note, neither normal
karyotype (ie, 47,XX/XY,121c), monosomy 7/7q2, aberrations of
chromosome13, or the long armof chromosome1 (1q)were associated
with apoor outcome (Table 2).Noneof thepatients that relapsedcarried
one of these cytogenetic aberrations. In contrast, ML-DS patients with
gain of chromosome 8 (18; n5 37) had a signiﬁcantly worse 5-year
EFS (73%6 8% vs 91%6 4%; PLog-Rank5 .017). The CIR/NR was
greatly increased (16%6 7%vs 3%6 2%;PGray5 .02). In fact, 5 of 7
relapsed patients with cytogenetic data had trisomy 8. The remaining 2
patients had isochromosome 7 (i[7]) or addition of material from
chromosome 16 (add[16]), respectively.Hence, no relapses occurred in
patientswithout gain of chromosome8, aberrations of chromosome 16,
or isochromosome 7 (n5 81).
Multivariate analysis
In themultivariate analysis for 5-year EFS, including sex, age, early
response, as well as cytogenetic subgroups (gain of chromosome 8,
aberrations of chromosome 16 or isochromosome 7) as risk factors,
poor early response (relative risk [RR]5 8.55; 95%CI, 1.96-37.29;
Px
2 5 .004) was of independent prognostic signiﬁcance (Table 3).
Also, gain of chromosome 8 was an independent prognostic factor
(RR 5 4.36; 95% CI, 1.24-15.39; Px
2 5 .022). The remaining
parameters were not of independent prognostic value.
Toxicity
DS patients are highly susceptible to therapy-induced toxicity. To
evaluate the toxicity of the ML-DS 2006 protocol, we analyzed the
treatment-related adverse events after each course. Severe adverse
events (CTCAE grade III or higher) were most frequently observed
after induction. Thirty-ﬁve percent of the ML-DS patients presented
with severe infections (Figure 3). Interestingly, the frequency of in-
fections declined in theML-DSpatients after eachblock so that after the
last course only 17% of the ML-DS patients presented with a grade III
(or higher) infection. Other recurrent severe adverse events affected the
skin or the gastrointestinal tract (vomiting/nausea, stomatitis, diarrhea)
or fatigue (asthenia, lethargy, malaise).
To assess the impact of excluding etoposide from consolidation on
toxicity, we compared the frequencies of treatment-related adverse
events to theAML-BFM98 trial (HAvsHAE; Figure 3). Fewer severe
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Figure 2. Outcome of ML-DS 2006 patients compared with the historical
control arm (AML-BFM 98). (A) EFS, (B) OS, and (C) CIR/NR for ML-DS 2006
patients in comparison with ML-DS children from the previous AML-BFM 98 trial9
(historical control arm). (A-C) Five-year probabilities are given.
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adverse events were reported after the HA block of the ML-DS 2006
trial compared with the HAE block of the AML-BFM 98 trial (RR,
0.559; 95% CI, 0.382-0.817). This was mainly attributed to a reduced
frequency of severe adverse events due to infections (16.8% vs 28.6%;
PFisherExact 5 .106), fever (3.5% vs 8.8%; PFisherExact 5 .164), nausea
(5.5% vs 11.3%; PFisherExact 5 .163), and fatigue (asthenia, lethargy,
malaise) (6.1% vs 15.5%; PFisherExact 5 .055), although this trend did
not reach signiﬁcance within each category. As expected, the analysis
of the remaining courses (AIE, AI, haM), which were identical
between the trials (except for CNS prophylaxis), did not show notable
differences (Figure 3).
Five patients died due to therapy (cardiac failure, n5 2; infections,
n5 3; Table 2) resulting in a TRM of 2.9% compared with 5% in the
historical control arm (AML-BFM 98; PFisherExact5 .276).
Discussion
ML-DS treatment schemata have to particularly strive for the balance
between appropriate chemotherapy dosage and treatment-related
toxicity.9-15 Here, we demonstrate that the international ML-DS 2006
Table 2. Five-year EFS/OS and CIR/NR of defined subgroups in the ML-DS 2006 study
N Events EFS, % P Deaths OS, % P Relapse/NR CIR/NR, % P
Total 170 19 87 16 89 9 6
Sex .008* .002* .330
Male 85 4 94 2 98 3 4
Female 85 15 79 14 81 6 8
Age, y .920 .740 .580
,1 24 2 91 1 96 1 5
1 88 10 86 8 89 3 4
2 43 6 84 6 86 4 10
$3 15 1 90 1 90 1 10
WBC, 3109/L .640 .680 .580
,5 79 12 82 10 86 6 9
5-10 65 5 91 4 93 2 3
10-15 9 1 89 1 89 — —
$15 12 1 90 1 88 1 10
Initial BM blasts, % .100 .100 .060
,20 74 12 81 11 83 7 11
$20 83 6 92 5 93 2 3
Early response, % BM blasts <.001* <.001* .01*
#5 123 12 88 9 92 4 4
.5 10 4 58 4 57 2 22
Case history, wk .076 .250 .070
,3 49 3 92 3 95 1 2
$3 44 8 79 6 83 5 13
TAM history .130 .280 .310
No 43 2 95 2 94 1 3
Yes 80 10 85 8 89 5 7
GATA1 .170 .220 .360
Mutated 98 11 87 9 90 5 6
WT 17 0 100 0 100 0 0
Cytogenetics 122
Normal (47,XY/XX 121c) .480 .330 .160
Yes 29 2 91 1 97 0 0
No 93 12 84 10 88 7 8
Gain of chr 8 .018* .071 .020*
Yes 37 8 73 6 77 5 16
No 85 6 91 5 95 2 3
Monosomy 7/7q2 .350 .460 .500
Yes 7 0 100 0 100 0 0
No 115 14 85 11 89 7 3
chr 13 aberrations .460 .520 .590
Yes 4 0 100 0 100 0 0
No 118 14 85 11 89 7 3
1q aberrations .260 .280 .430
Yes 10 0 100 0 100 0 0
No 112 14 85 11 88 7 3
chr 16 aberrations/ i(7) .001* <.001* <.001*
Yes 4 2 38 2 33 2 63
No 118 12 87 9 91 5 5
—, none.
*Bold P values are significant (,.05).
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study achieved an excellent outcome (5-year OS, 89% 6 3%; 5-year
EFS, 87% 6 3%) for these children with tolerable toxicity. We es-
tablished early response after 1 course of chemotherapy and trisomy 8
as independent prognostic markers.
The ML-DS 2006 trial was based on the reduced-intensity arm for
ML-DS patients of the AML-BFM 98 trial. Due to the excellent
outcome of the ML-DS patients in the AML-BFM 98 trial (n5 67;
5-year OS, 90%6 4%; 5-year EFS, 896 4), the treatment intensity
was further reduced in the ML-DS 2006 trial by excluding
etoposide from consolidation, administering 4 instead 11 doses
of intrathecal CNS prophylaxis and excluding maintenance therapy.
Despite this reduction, the outcome in both studies was in a
similar range. The CIR/NR especially was identical in both studies
(6%), validating that therapy reduction did not result in a higher
relapse risk. The absence of CNS involvement in any of the
patients might suggest that the ML-DS blasts cannot home to this
niche and explain why we did not observe an increase in CNS
relapses despite reduction of CNS prophylaxis. Although the TRM
was not signiﬁcantly reduced (2.9% vs 5%; PFisherExact 5 .276),
excluding etoposide resulted in fewer severe adverse events after
consolidation. However, the nonrandomized trial design and the
comparison with a historical control is a potential weakness of
the study, which was necessary due to the low number of ML-DS
patients per year (expected accrual, 20 patients per year), and the
expected low compliance with a more intense treatment arm. Still,
the data may implicate that even further reduction of treatment
intensity could be feasible based on prognostic factors.
Despite a general consent about longer treatment intervals and
the discouraging role of hematopoietic stem cell transplantation,
international study protocols for ML-DS differ substantially
(Table 4).9-15 The role of high-dose cytarabine and the dosing of
anthracyclines especially have yet to be deﬁned. Whereas in most
European and North American trials for ML-DS courses with high-
dose cytarabine (3 g/m2 per day) are applied,9-12 Japanese studies
(Japan Pediatric Leukemia/Lymphoma Study Group [JPLSG]
AML D05) obtained excellent results (3-year OS: 88% 6 4%
3-year EFS: 83%6 4%) and low TRM (1.4%) using standard-dose
cytarabine (100mg/m2 per day) only.15 Together with the results of
the Toronto group that used a low-dose cytarabine-based regimen,13,32
which contained no anthracyclines and no etoposide, these data
indicate that subgroups of patients with ML-DS can be cured even
with much lower doses than in the current ML-DS 2006 trial. But the
identiﬁcation of clear prognostic factors that would predict which
patients are at risk of relapse and need intense therapy remained
elusive.21
Our study makes a signiﬁcant step toward risk-adapted therapy
in ML-DS. We show that the early therapy response, assessed by
morphology at the start of the second block, is predictive of treat-
ment outcome and relapse. Future trials will need to show whether
monitoring of minimal residual disease could even increase this
predictive value. Most importantly, however, our analysis showed
Table 3. Multivariable Cox regression analysis of clinical factors
and cytogenetics for EFS
N 5 101 RR 95% CI P
Sex 3.65 0.76-17.48 .105
Age ,2 y 2.29 0.57-9.21 .244
Trisomy 8 4.36 1.24-15.39 .022*
chr 16 aberrations/i(7) 3.92 0.38-40.82 .253
Early response 8.55 1.96-37.29 .004
*Bold P value is significant (,.05).
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Figure 3. Treatment-related toxicity of ML-DS 2006 patients. Percentage of ML-DS patients with severe adverse events (CTCAE grade III or higher) after each block of
chemotherapy in comparison with the ML-DS patients, treated according to the AML-BFM 98 protocol. Only P values (Fisher exact)#.2 are shown. All other comparisons are
PFisherExact . .2. ALT, alanine transaminase; AST, aspartate transaminase.
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that all relapses were in the cytogenetic groups of patients with
trisomy 8, aberration of chromosome 16, or isochromosome 7.
This means that none of the patients belonging to the other
cytogenetic subgroups (n 5 81) experienced a relapse. This
includes patients with cytogenetic aberrations which were previously
proposed to be associated with higher relapse risk, such as mono-
somy 7 or normal karyotype (ie, 47,XX/XY,121c).14,21 Although
the cytogenetic groups are small, limiting the conﬁdence of the
subgroup analysis, they are in accordance with a recent Japanese
study15 that could neither conﬁrm monosomy 7 nor normal karyo-
type as poor prognostic factors. Thus, reproducible and consistent
data across the study groups imply that monosomy 7 and normal
karyotype are not predictive for poor prognosis. Instead, our data
indicate gain of chromosome 8 to predict a high relapse risk and
poor EFS.
Despite the use of high-dose cytarabine, we observed a TRM of
2.9% (n 5 5 of 170 patients), which is in the same range as the
Children’s OncologyGroup (COG)A2971 trial12 (2.3%; n5 3 of 132;
PFisherExact 5 1.000) that also used high-dose cytarabine, and which
does not signiﬁcantly differ from the JPSLG AML D05 trial15 (1.4%;
n 5 1/72; PFisherExact 5 0.673) that used standard-dose cytarabine.
Three patients died due to infections (Streptococcus mitis sepsis,
fungal sepsis, and respiratory syncytial virus pneumonia, re-
spectively). This is in contrast to a previous study which included
theGermanML-DS patients of theML-DS 2006 trial and theAML-
BFM 98 trial and found that all deaths due to infections were
attributed to respiratory syncytial virus pneumonia.33 Two patients
died due to cardiac failure, underscoring the sensitivity of children
with DS to cardiotoxic agents. Thus, lowering cardiotoxicity, for
example, by introducing liposomal formulations of daunorubi-
cin,34 should be an aim for the development of future treatment
protocols.
Our study demonstrates that ML-DS is not necessarily associ-
ated with high treatment-related toxicity even when compared with
non-DS-AML patients (supplemental Figure 1). Knowing the high
susceptibility of DS patients to cytostatic agents, this observa-
tion might be explained by 2 factors. First, ML-DS patients do not
obtain 1 very intense course (high-dose cytarabine andmitoxantrone
[HAM]) and the anthracycline doses are reduced in all courses.
Second, the treatment intervals for ML-DS patients are longer
(median interval between ﬁrst [AIE] and second course [AI/HAM]
for ML-DS vs non-DS-AML, 32 vs 25 days; P , .001) giving the
patients more time to recover after each course; that is, a block was
only started if the child showed recovery of blood counts and was
in good general condition without clinical signs of an infection,
mucositis, or fever.
Recently, wee1 kinase inhibitors35 or histone deacetylase inhib-
itors36,37 have been identiﬁed as promising classes of drugs for the
future treatment of ML-DS. Those drugs can be introduced to up-
coming ML-DS protocols to substitute other less tolerated chemo-
therapeutic agents while increasing/maintaining overall efﬁcacy.
With the dismal outcomes after relapse especially (7 of 9 relapsed
patients died in the ML-DS 2006 trial), these new substances may
help to further reduce therapy-related toxicity while preventing
relapses.19
In summary, we show that therapy reduction could be achieved in
children with ML-DS without compromising the excellent outcome.
The identiﬁcation of clinical and cytogenetic prognostic markers
in our study offers new possibilities for risk-adapted therapy for
childrenwithML-DS. Thiswill help to further reduce therapy in low-
risk patients and intensify treatment in high-risk patients to avoid
relapses.
Acknowledgments
The authors thank all colleagues, data managers, and technicians
of the participating hospitals for their valuable cooperation. The
authors thank J. E. Mu¨ller (Hannover, Germany) for competent data
management.
This work was supported by the Deutsche Krebshilfe e.V.
and Beat Leukemia with Connor. J.-H.K. is a fellow of the Emmy
Noether-Programme from the German Research Foundation (DFG;
KL-2374/2-1).
Authorship
Contribution: U.C., H.H., C.M.Z., D.R., and J.-H.K. conceived and
designed the study; H.H., C.M.Z., D.R., and J.-H.K. provided
ﬁnancial and administrative support; M.D., H.H., C.M.Z., D.R., and
J.-H.K. provided study materials or patients; M.U., M.R., C.v.N.,
L.S.,M.D., H.H., C.M.Z., D.R., and J.-H.K. collected and assembled
data;M.U.,M.R., C.v.N.,M.Z., and J.-H.K. analyzed and interpreted
data; M.U. and J.-H.K. wrote the manuscript; and all authors gave
ﬁnal approval of manuscript.
Conﬂict-of-interest disclosure: D.R. has consulting or advisory
roles for Celgene, Pﬁzer, MSD, Astellas Pharma, Novartis, and
Boehringer and receives research funding from Celgene. C.M.Z. has
consulting or advisory roles for Pﬁzer, Daiichi Sankyo, Celgene,
Novartis, Bristol-Myers Squibb, and Gilead Sciences and receives
research funding from Karyopharm Therapeutics, Pﬁzer, Bristol-
Myers Squibb, and GlaxoSmithKline. M.D. receives research
funding from Beckman Coulter and Becton Dickinson. H.H. has
a consulting or advisory role for Celgene. The remaining authors
declare no competing ﬁnancial interests.
ORCID proﬁles: J.-H.K., 0000-0002-1070-0727.
Correspondence: Jan-HenningKlusmann,Department of Pediatric
Hematology andOncology,HannoverMedical School, Carl-Neuberg-
Str 1, 30625 Hannover, Germany; e-mail: klusmann.jan-henning@
mh-hannover.de.
Table 4. Comparison of recent ML-DS trials
Years N DNR, mg/m2 ARA-C, mg/m2 Etoposide, mg/m2 TRM, % 5-y OS, % 5-y EFS, % Reference
ML-DS-06 2006-2015 170 240 27 400 450 2.9 89 87
AML-BFM 98 1998-2003 204 240 29 400 950 5.0 90 89 9
COG A2971 1999-2003 132 320 27 200 0* 2.3 84 79 12
Al-Ahmari 1990-2003 34 0 7 400 0 0 77 67 33
JPLSG D05 2008-2010 72 250 3 500 1350 1.4 88 83 15
ARA-C, cytarabine; DNR, daunorubicin.
*6-Thioguanine, 1600 mg/m2; L-asparaginase, 12 000 IU/m2.
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